Skip to main content
Publications
Hamadani M, Spira AI, Zhou X, Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150
Bommireddy R, Pack CD, Bozeman EN, Patel JM, Vartebedian VF, Munoz LE, Shafizadeh Y, Menon AP, Lakshmanan R, Reddy SJC, Selvaraj P. Membrane-based immunotherapy with immune checkpoint blockade antibodies confers protection against metastatic breast cancer. Poster presented at the Immunology 2017 Meeting; May 12, 2017. Washington, DC. [abstract] J Immunol. 2017 May 1; 198(1_Supplement):120.8. doi: 10.4049/jimmunol.198.Supp.120.8
Munoz LE, Bommireddy R, Margaroli C, Shafizadeh Y, Bozeman EN, Menon AP, Kumar J, Lakshmanan R, Selvaraj P. HER-2+ breast cancer cells expressing GPI-anchored cytokines induce long lasting antitumor memory response. Poster presented at the Immunology 2017 Meeting; May 12, 2017. Washington, DC. [abstract] J Immunol. 2017 May 1; 198(1_Supplement):79.28. Previously presented at the International Congress of Immunology (ICI) 2016. doi: 10.4049/jimmunol.198.Supp.79.28